Glenmabusumab-vedotin demonstrated encouraging efficacy in treating triple-negative breast cancer (TNBC) in the CR011-CLN-20 study and the ensuing EMERGE analysis, especially in patients whose tumors overexpress gpNMB (glycoprotein NMB). The gene discussed is GPNMB; the disease is triple-negative breast carcinoma.